According to a published study, Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) two-dose COVID-19 vaccine provided very little protection for children aged 5 to 11 years during the wave of omicron infection in New York.
The vaccine's efficacy against infection among those children declined to 12% at the end of January from 68% in mid-December compared to kids who did not get vaccinated, according to the study, which has not yet been peer-reviewed.
